About ATG:biosynthetics
ATG:biosynthetics is a Healthcare company based in Merzhausen (Germany) founded in 2001. Technology platform for gene synthesis is provided. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its legal entity is ATG-Biosynthetics GmbH.
Company details
ATG:biosynthetics was established in 2001 in Merzhausen, Germany, within the biotechnology sector. Services focused on gene synthesis, including multi-gene and multi-protein expression products, are offered alongside customized solutions for gene optimization, expression systems, and synthetic bioinformatics. Complex combinatorial gene and gene-cluster designs, as well as multi-gene expression strategies, are enabled through this platform. Clients such as pharmaceutical companies, molecular diagnostics firms, and bioengineering entities are served.
- Headquarters Merzhausen, Germany
- SectorsHealthcare
- Email••••••••
- Website atg-biosynthetics.com
- Social LinkedIn
- Legal Name Atg-Biosynthetics Gmbh.
- Latest Funding Round$966.46K (USD), Grant
Apr 2015
- Investors
Funding Insights of ATG:biosynthetics
- Total Rounds 1
- Last Round Grant — $966,456
- First Round $966,456
(Apr 2015)
- Investors Count 1
All 1 funding rounds of ATG:biosynthetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | $966,456 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in ATG:biosynthetics
ATG:biosynthetics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ATG:biosynthetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ATG:biosynthetics
2 dated milestones of ATG:biosynthetics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ATG:biosynthetics is founded.
- Funding First funding round of $966K.
Web traffic of ATG:biosynthetics
The website of ATG:biosynthetics (atg-biosynthetics.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 3.9% vs previous month
Websites whose visitors overlap most with ATG:biosynthetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bitesizebio.com | 100% | 153.3K | #313,861 | View details | |
portals.iucn.org | portals.iucn.org | 80% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ATG:biosynthetics
ATG:biosynthetics was founded in 2001 and raised its 1st funding round 14 years after it was founded.
ATG:biosynthetics is headquartered in Merzhausen, Germany. It is registered at Merzhausen, Baden-wurttemberg, Germany.
ATG:biosynthetics was established in 2001 in Merzhausen, Germany, within the biotechnology sector. Services focused on gene synthesis, including multi-gene and multi-protein expression products, are offered alongside customized solutions for gene optimization, expression systems, and synthetic bioinformatics. Complex combinatorial gene and gene-cluster designs, as well as multi-gene expression strategies, are enabled through this platform. Clients such as pharmaceutical companies, molecular diagnostics firms, and bioengineering entities are served.
ATG:biosynthetics has 1 investor. Key investors include European Union.
ATG:biosynthetics operates through Atg-Biosynthetics Gmbh..